169 related articles for article (PubMed ID: 29883599)
1. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014.
Kern WV; Weber S; Dettenkofer M; Kaier K; Bertz H; Behnke M; Weisser M; Götting T; Widmer AF; Theilacker C;
J Infect; 2018 Jul; 77(1):68-74. PubMed ID: 29883599
[TBL] [Abstract][Full Text] [Related]
2. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
3. Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.
Widmer AF; Kern WV; Roth JA; Dettenkofer M; Goetting T; Bertz H; Theilacker C;
Infection; 2019 Oct; 47(5):837-845. PubMed ID: 31187401
[TBL] [Abstract][Full Text] [Related]
4. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.
Verlinden A; Jansens H; Goossens H; van de Velde AL; Schroyens WA; Berneman ZN; Gadisseur AP
Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.
Mikulska M; Averbuch D; Tissot F; Cordonnier C; Akova M; Calandra T; Ceppi M; Bruzzi P; Viscoli C;
J Infect; 2018 Jan; 76(1):20-37. PubMed ID: 29079323
[TBL] [Abstract][Full Text] [Related]
7. A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia.
Yemm KE; Barreto JN; Mara KC; Dierkhising RA; Gangat N; Tosh PK
J Antimicrob Chemother; 2018 Jan; 73(1):204-211. PubMed ID: 29040595
[TBL] [Abstract][Full Text] [Related]
8. Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency.
Sanna M; Caocci G; Orrù F; Ledda A; Vacca A; Piras E; Fozza C; Deias P; Tidore G; Dore F; La Nasa G
J Clin Pharm Ther; 2017 Dec; 42(6):733-737. PubMed ID: 28597476
[TBL] [Abstract][Full Text] [Related]
9. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
10. Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS).
Weisser M; Theilacker C; Tschudin Sutter S; Babikir R; Bertz H; Götting T; Dettenkofer M; Kern WV; Widmer AF;
Clin Microbiol Infect; 2017 Nov; 23(11):854-859. PubMed ID: 28366613
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
Kern WV; Klose K; Jellen-Ritter AS; Oethinger M; Bohnert J; Kern P; Reuter S; von Baum H; Marre R
Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):111-8. PubMed ID: 15714332
[TBL] [Abstract][Full Text] [Related]
12. Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: Results from a multicentric surveillance cohort study.
Kern WV; Roth JA; Bertz H; Götting T; Dettenkofer M; Widmer AF; Theilacker C;
Transpl Infect Dis; 2019 Dec; 21(6):e13186. PubMed ID: 31574202
[TBL] [Abstract][Full Text] [Related]
13. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.
Gudiol C; Bodro M; Simonetti A; Tubau F; González-Barca E; Cisnal M; Domingo-Domenech E; Jiménez L; Carratalà J
Clin Microbiol Infect; 2013 May; 19(5):474-9. PubMed ID: 22524597
[TBL] [Abstract][Full Text] [Related]
14. [Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].
Sinkó J; Cser V; Konkoly Thege M; Masszi T
Orv Hetil; 2011 Jul; 152(27):1063-7. PubMed ID: 21676672
[TBL] [Abstract][Full Text] [Related]
15. Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey.
Trecarichi EM; Giuliano G; Cattaneo C; Ballanti S; Criscuolo M; Candoni A; Marchesi F; Laurino M; Dargenio M; Fanci R; Cefalo M; Delia M; Spolzino A; Maracci L; Nadali G; Busca A; Del Principe MI; Daffini R; Simonetti E; Dragonetti G; Zannier ME; Pagano L; Tumbarello M;
PLoS One; 2019; 14(10):e0224465. PubMed ID: 31661507
[TBL] [Abstract][Full Text] [Related]
16. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis.
Busca A; Cavecchia I; Locatelli F; D'Ardia S; De Rosa FG; Marmont F; Ciccone G; Baldi I; Serra R; Gaido E; Falda M
Transpl Infect Dis; 2012 Feb; 14(1):40-8. PubMed ID: 21599817
[TBL] [Abstract][Full Text] [Related]
17. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Blennow O; Ljungman P; Sparrelid E; Mattsson J; Remberger M
Transpl Infect Dis; 2014 Feb; 16(1):106-14. PubMed ID: 24372809
[TBL] [Abstract][Full Text] [Related]
18. Bloodstream infections in neutropenic patients with haematological malignancies.
Carvalho AS; Lagana D; Catford J; Shaw D; Bak N
Infect Dis Health; 2020 Feb; 25(1):22-29. PubMed ID: 31586572
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.
Kara Ö; Zarakolu P; Aşçioğlu S; Etgül S; Uz B; Büyükaşik Y; Akova M
Infect Dis (Lond); 2015; 47(10):686-93. PubMed ID: 26024284
[TBL] [Abstract][Full Text] [Related]
20. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Martino R; Subira M; Altés A; López R; Sureda A; Domingo-Albós A; Pericas R; Brunet S
Acta Haematol; 1998; 99(4):206-11. PubMed ID: 9644298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
